Ensysce Biosciences, Inc.
ENSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.70 | 0.04 | 0.02 | 0.00 |
| FCF Yield | -52,759,451.44% | -29.95% | -73.64% | -0.58% |
| EV / EBITDA | -1.64 | -3.33 | -1.06 | -71.79 |
| Quality | ||||
| ROIC | -182.30% | -4,663.69% | -3,388.80% | -156.35% |
| Gross Margin | -38.57% | -240.12% | -686.17% | 100.00% |
| Cash Conversion Ratio | 939,362.91 | 1.01 | 0.74 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.34% | -14.19% | -13.74% | 26.03% |
| Free Cash Flow Growth | -69,598,346.45% | 39.73% | -117.02% | -560.78% |
| Safety | ||||
| Net Debt / EBITDA | 0.48 | 0.03 | -0.05 | -0.25 |
| Interest Coverage | -5.22 | -30.28 | -221.15 | -15.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -71.66 | -0.00 |
| Cash Conversion Cycle | -59.92 | -77.18 | -19.21 | -1,795,524.70 |